Dichloroacetate attenuates experimental acute liver injury and reduces hepatocyte apoptosis
- 1Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University
- 2Department of Clinical Nutrition, The Second Affiliated Hospital, Chongqing Medical University
Abstract
Background: Acute liver injury (ALI) is a severe clinical condition characterized by rapid hepatic dysfunction and may progress to acute liver failure. Hepatocyte apoptosis is a critical pathological event in ALI. Dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase, has been reported to regulate cellular metabolism and apoptosis; however, its role in ALI remains unclear. This study investigated the protective effects and potential mechanisms of DCA in experimental ALI.
Methods: DCA was evaluated in mouse models of ALI induced by lipopolysaccharide (LPS)/d-galactosamine (D-GalN) or tumor necrosis factor-α (TNF-α)/D-GalN. Liver injury and hepatocyte apoptosis were assessed by serum transaminase activities, histopathology, and TUNEL staining. Hepatic immune cell profiles were analyzed by flow cytometry. Hepatic cytokine mRNA expression and serum cytokine levels were measured by RT-qPCR and ELISA, respectively. Apoptosis-related proteins were examined by Western blotting. Additional acetaminophen (APAP) and thioacetamide (TAA) models were used to assess DCA-mediated hepatoprotection.
Results: DCA pretreatment substantially attenuated LPS/D-GalN-induced ALI, as evidenced by reduced serum transaminase levels, less severe histopathological injury, and decreased hepatocyte apoptosis. This hepatoprotective effect was not accompanied by significant changes in surface TLR4 abundance on Kupffer cells, serum inflammatory cytokine levels, or hepatic immune cell composition at the examined time points. Notably, DCA treatment was associated with reduced cleaved caspase-3 expression and increased A20 protein levels in both LPS/D-GalN- and TNF-α/D-GalN-treated mice.
Conclusion: DCA attenuates experimental ALI and is associated with reduced hepatocyte apoptosis and increased A20 expression.
Related
- Tacrolimus attenuates BCL-2/BAX-mediated chondrocyte apoptosis and cartilage matrix degradation in experimental osteoarthritis
- The NF-κB-TNFAIP3 axis attenuates MASLD via activation of hepatocyte autophagy.
- Luteolin protects against cholestasis by suppressing hepatocyte apoptosis through direct PI3K binding and AKT activation
- A nitric oxide donating β-elemene derivative induces reactive oxygen species associated apoptosis and reduces STAT3 phosphorylation in medulloblastoma cells
- Early intermittent low-dose sclerostin antibody treatment promotes surface bone formation and reduces bone loss, but also decreases osteocyte apoptosis and mechanotransduction in ovariectomized rats: A pilot study
BibTeX
@article{xiang2026dichloroacetate,
title = {{Dichloroacetate attenuates experimental acute liver injury and reduces hepatocyte apoptosis}},
author = {Feng Xiang and Shiwen Tong and Wenwei Yin},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1919667},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1919667/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Dichloroacetate attenuates experimental acute liver injury and reduces hepatocyte apoptosis
AU - Feng Xiang
AU - Shiwen Tong
AU - Wenwei Yin
PY - 2026
DA - 2026/10/26
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1919667
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1919667/full
AB - Background: Acute liver injury (ALI) is a severe clinical condition characterized by rapid hepatic dysfunction and may progress to acute liver failure. Hepatocyte apoptosis is a critical pathological event in ALI. Dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase, has been reported to regulate cellular metabolism and apoptosis; however, its role in ALI remains unclear. This study investigated the protective effects and potential mechanisms of DCA in experimental ALI. Methods: DCA was evaluated in mouse models of ALI induced by lipopolysaccharide (LPS)/d-galactosamine (D-GalN) or tumor necrosis factor-α (TNF-α)/D-GalN. Liver injury and hepatocyte apoptosis were assessed by serum transaminase activities, histopathology, and TUNEL staining. Hepatic immune cell profiles were analyzed by flow cytometry. Hepatic cytokine mRNA expression and serum cytokine levels were measured by RT-qPCR and ELISA, respectively. Apoptosis-related proteins were examined by Western blotting. Additional acetaminophen (APAP) and thioacetamide (TAA) models were used to assess DCA-mediated hepatoprotection. Results: DCA pretreatment substantially attenuated LPS/D-GalN-induced ALI, as evidenced by reduced serum transaminase levels, less severe histopathological injury, and decreased hepatocyte apoptosis. This hepatoprotective effect was not accompanied by significant changes in surface TLR4 abundance on Kupffer cells, serum inflammatory cytokine levels, or hepatic immune cell composition at the examined time points. Notably, DCA treatment was associated with reduced cleaved caspase-3 expression and increased A20 protein levels in both LPS/D-GalN- and TNF-α/D-GalN-treated mice. Conclusion: DCA attenuates experimental ALI and is associated with reduced hepatocyte apoptosis and increased A20 expression.
SN - 1663-9812
ER -